Business Context and Reporting Period
Company: Capstone Therapeutics Corp. (formerly OrthoLogic Corp.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: A development-stage biotechnology company focused on two product platforms: AZX100 (a peptide for scarring and fibrosis) and Chrysalin (a peptide for tissue repair and angiogenesis). The company sold its former bone device business in 2003 and currently has no revenue-generating operations.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2010 | Six Months Ended June 30, 2010 | Balance Sheet (June 30, 2010) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2,923,000) | $(5,874,000) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.07) | $(0.14) | N/A |
| Operating Expenses | $(2,949,000) | $(5,945,000) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $9,131,000 |
| Short-term Investments | N/A | N/A | $20,873,000 |
| Total Current Assets | N/A | N/A | $30,475,000 |
| Total Current Liabilities | N/A | N/A | $1,769,000 |
| Accumulated Deficit | N/A | N/A | $(173,191,000) |
| Potentially Redeemable Equity | N/A | N/A | $13,382,000 |
Note: All figures in thousands except per share data.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $193,000 for the three months ended June 30, 2010, compared to the same period in 2009. For the six-month period, the loss decreased by $1,390,000.
- Expense Drivers: The reduction in loss is primarily attributed to a decrease in Research and Development (R&D) expenses ($419,000 decrease for the quarter; $2,004,000 decrease for the six months). This was due to the completion of planned partnering research activities for Chrysalin in 2009 and a one-time peptide purchase in 2009.
- Interest Income Decline: Interest and other income, net, dropped significantly from $224,000 to $26,000 for the quarter (and $491,000 to $71,000 for the six months) due to lower interest rates and reduced investment balances.
- Balance Sheet Reclassification: A new line item, "Potentially Redeemable Equity" of $13,382,000, appeared on the balance sheet due to the accounting treatment of shareholder Put Rights approved in May 2010.
Guidance, Outlook, and Risks
- Operational Focus: The company continues Phase 2 clinical trials for AZX100 (dermal scarring) and pre-clinical studies. For Chrysalin, the strategy has shifted from independent clinical trials to seeking development partnerships or licensing opportunities.
- Liquidity Outlook: Management anticipates that current cash and short-term investments ($30 million total) are sufficient to meet projected requirements for the next year. However, completing full clinical trials and FDA approval for either product will require additional capital.
- Put Rights Risk: Shareholders approved "Put Rights" exercisable on or about July 31, 2011. This allows shareholders to require the company to purchase their shares for cash based on a formula (approx. 90% of available cash per share). The company has reclassified $13.4 million to a redemption reserve. Exercise of these rights could materially impact liquidity and operations.
- Legal Contingency: A qui tam complaint regarding the former bone device business (sold in 2003) remains pending. The company intends to dismiss the complaint and does not believe it will have a material adverse effect.
Investor Verification Checklist
- Cash Runway: Verify if the $30 million in liquid assets is sufficient to fund AZX100 Phase 2 trials through 2011 without raising new capital.
- Put Rights Impact: Assess the potential cash outflow if a significant portion of shareholders exercise the Put Rights in July 2011.
- Partnership Progress: Monitor announcements regarding partnership or licensing deals for Chrysalin, as the company has ceased independent clinical development for this asset.
- AZX100 Trial Data: Await results from the Phase 2 clinical trials for dermal scarring, which are targeted for substantial completion in 2010.
- Legal Status: Confirm the status of the pending motion to dismiss the qui tam lawsuit related to the legacy bone device business.